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Background: Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma. We developed and validated a
clinical prediction scale for response to anti- PD-1 monotherapy.
Methods: A total of 315 patients with advanced melanoma treated with pembrolizumab (2 or 10mgkg 1 Q2W or Q3W) or
nivolumab (3mg kg 1 Q2W) at four cancer centres between 2011 to 2013 served as the setting for the present cohort study.
Variables with significant association to response on a univariate analysis were entered into a forward stepwise logistic regression
model and were given a score based on ORs to calculate a clinical prediction scale.
Results: The developed clinical prediction scale included elevated LDH (1 point), age o65 years (1 point), female sex (1 point),
history of ipilimumab treatment (2 points) and the presence of liver metastasis (2 points). The scale had an area under the receiver-
operating curve (AUC) of 0.73 (95% CI 0.67, 0.80) in predicting response to therapy. The predictive performance of the score was
maintained in the validation cohort (AUC 0.70 (95% CI 0.58, 0.81)) and the goodness-to-fit model demonstrated good calibration.
Conclusions: Based on a large cohort of patients, we developed and validated a simple five-factor prediction scale for the clinical
activity of PD-1 antibodies in advanced melanoma patients. This scale can be used to stratify patients participating in clinical trials.
The treatment of melanoma has been transformed in recent
years by novel targeted therapies and immunotherapy. Namely,
molecularly targeted combinations for patients with BRAF
mutations, such as dabrafenib plus trametinib or vemurafenib
plus cobimetinib, and immunotherapies, such as the CTLA-4
blocking antibody ipilimumab (Robert et al, 2015b) and the PD-1
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blocking antibodies nivolumab and pembrolizumab, have signifi-
cantly improved survival for patients with advanced melanoma
(Robert et al, 2011; Ribas et al, 2015).
The PD-1 receptor is an inhibitory receptor expressed on
activated T and B cells. Its primary ligand, PD-L1, is frequently
expressed within the tumour microenvironment such as cancer
cells and tumour-infiltrating macrophages. The second ligand,
PD-L2, is preferentially expressed by antigen presenting cells
(Blank et al, 2004; Pardoll, 2012; Sullivan et al, 2013).
In the initial phase I clinical trial with nivolumab, Brahmer et al
(2010) reported dramatic clinical activity with tumour regressions
in several tumour types: colon, renal, lung cancers, and melanoma.
Pembrolizumab was initially evaluated in a large phase I trial
(KEYNOTE-001). In a pooled analysis of 411 advanced melanoma
patients, the response rate was 34% after a median follow-up of 18
months and was maintained in 81% of those patients with a
median overall survival of 25.9 months (Hamid et al, 2013;
Deeks, 2016; Ribas et al, 2016). Results from two other trials,
KEYNOTE-002 and KEYNOTE-006, have since been reported
(Ribas et al, 2015; Robert et al, 2015b). Two pembrolizumab
dosages (2 or 10mg kg 1 every 3 weeks) were compared with
investigator’s-choice chemotherapy in patients with ipilimumab-
refractory advanced melanoma in KEYNOTE-002. Pembrolizumab
demonstrated superior progression-free survival compared with
chemotherapy (Ribas et al, 2015). Pembrolizumab (10mg kg 1
every 2 or every 3 weeks) was also compared with ipilimumab
(3mg kg 1 every 3 weeks) in 834 advanced melanoma patients in
KEYNOTE-006 and found significantly improved overall survival
compared with ipilimumab (Robert et al, 2015b). Additionally,
nivolumab (3mg kg 1 every 2 weeks) was compared with
dacarbazine (1000mg kg 1 every 3 weeks) in a phase 3, double-
blind, randomised control trial in 418 untreated patients and was
associated with significant improvement in overall survival and
progression-free survival (Robert et al, 2015a). These trials have
established PD-1 antibodies as an important treatment modality
for melanoma.
Although PD-1 blockade represents a major step forward, many
patients still fail to respond to this drug. The mechanisms
underlying this clinical heterogeneity are currently unknown and
may be associated with both tumour intrinsic and extrinsic factors
(Blank et al, 2016; Pitt et al, 2016). Thus the identification of a
clinical predictive model for response is critical due to the
following reasons: (1) To allow patients who are unlikely to
benefit from anti-PD-1 therapy to be spared from unnecessary risk
of toxicity and to rationally select a combination that will better fit
them (Hiniker et al, 2015). (2) To spare those who are likely to
respond to PD-1 monotherapy from unnecessary toxicities of a
combination immunotherapy approach.
Biomarkers associated with both tumour intrinsic and extrinsic
factors have been recently investigated, however, none have yet
been established to clearly predict response to anti-PD-1 mono-
therapy (Weide et al, 2016). Previous studies that assayed PD-L1
expression on tumour cells using traditional immunohistochemical
approaches reported an association between high expression and
clinical response to pembrolizumab (Kefford et al, 2014) or
nivolumab (Topalian et al, 2012; Weber et al, 2013; Taube et al,
2014). The tumour immune phenotype has also been investigated,
and CD8þ T cells have been suggested as a potential biomarker in
several studies; Tumeh et al (2014) reported that preexisting CD8þ
T cells in the tumour microenvironment were required for tumour
regression after treatment with pembrolizumab. Additionally, our
group has recently reported relative abundance of ‘exhausted’ or
PD-1/CTLA-4 dual-positive CD8 cells as a biomarker to predict
response to anti-PD-1, using a multiparameter flow cytometry on
freshly isolated melanoma samples (Daud et al, 2016). Other
clinical and pathological factors associated with favourable overall
survival were reported recently by Weide et al (2016) and included:
low pretreatment values of LDH, limited visceral tumour burden,
high relative eosinophil count, and high relative lymphocyte count.
Although some preliminary biomarkers have been suggested, no
clinical prediction scale has been created that can be used widely.
To fill this gap, we sought to investigate readily available variables
and develop and validate a simple clinical prediction scale for
response to anti-PD-1 in advanced melanoma patients.
MATERIALS AND METHODS
Study design. Our study cohort consisted of 337 patients
diagnosed with advanced melanoma and treated with either
pembrolizumab (2 or 10mg kg 1 Q2W or Q3W) or nivolumab
(3mg kg 1 Q2W) at four cancer centres: UCSF, UCLA, The
Angeles Clinic and Research Institute (TACRI), and University
Hospital of Zu¨rich (USZ) between December 2011 to October
2013. Patients received immunotherapy as part of standard of care
treatment or on the following clinical trials: KEYNOTE-001
(NCT01295827), KEYNOTE-002 (NCT01704287), KEYNOTE-
006 (NCT01866319), or EAP (NCT02083484). All patients
enrolled on these trials at any of the four centres were included
in our study. Our final cohort consisted of 315 patients with
advanced unresectable cutaneous or mucosal melanoma agedX18
years treated with either pembrolizumab (N¼ 304) or nivolumab
(N¼ 11). Patients with uveal melanoma were excluded (n¼ 22).
The final data set was divided into derivation and validation
cohorts. The derivation cohort consisted of 228 patients from the
following institutes: UCSF, UCLA, and USZ. The validation cohort
consisted of 87 patients from TACRI (Figure 1). The study was
approved by the Institutional Review Board at the University of
California, San Francisco, CA, USA.
Data collection. The electronic medical records of the 315
patients were reviewed. Data points collected included, but were
not limited to, patient’s demographics (sex, age), melanoma
primary site, laboratory values (LDH, WBC), AJCC staging,
metastatic status, Eastern Cooperative Oncology Group (ECOG)
performance status, BRAF mutation status, previous therapies, and
best overall response.
Treatment outcomes. The primary outcome measure was tumour
response to treatment, which was evaluated using CT imaging at 12
and 16 weeks after the first infusion, and every 12 weeks thereafter.
The Response Evaluation Criteria in Solid Tumors (RECIST) version
1.1 was used to define objective clinical responses by a investigator-
adjudicated review. Sites of metastases were determined using CT
imaging and were not limited to RECIST-defined target lesions. The
primary site of melanoma was based on clinical documentation
prior to enrollment. Two treatment outcome groups, responders and
non-responders, were defined using CT imaging following the
treatment. Responders included patients with tumour target lesion
that met RECIST v1.1 criteria for complete response (499%
reduction in the tumour size) or partial response (X30% radio-
graphic reduction in tumour size). Non-responders included
patients with tumour target lesions that met RECIST 1.1 criteria
for progression (X20% increase in the target lesion) or stable disease
(o30% reduction or o20% increase in tumour target lesions).
Statistical analysis. Patient characteristics are summarised using
means and s.d. for continuous variables and percentages for
categorical variables. The final data set was divided into two parts:
the derivation and the validation cohorts. The derivation cohort
was used to develop the clinical prediction scale for tumour response,
and the validation cohort was used to assess how well the scale
predicted tumour response. LDH was analysed by the means of
LDH-ratio (LDH value divided by the institutional upper limit of
normal). Abnormal LDH was set at a cutoff of ‘1’ (LDH ratio 41).
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Logistic regression was used to assess the possible association
between response to anti-PD-1 and the following set of prespecified
variables: age, sex, primary site, abnormal LDH, WBC, ECOG
performance status, liver metastasis, lung metastasis, brain metastasis,
history of ipilimumab treatment, BRAF mutation status, metastatic
stage, and history of treatment with targeted therapy.
Variables with significant association on univariate analysis
were entered into a stepwise logistic regression model; the P value
threshold to enter/leave the model was set to 0.05. A simple and
easy clinical tumour response prediction formula, which produces
a score for each subject ranging from 0 to 7, was developed using
the estimated coefficients of the variables in the final model.
To assess the performance of the score, the formula was used to
calculate scores for the validation cohort, and the resulting scores
were used to predict tumour response. Discrimination of
performance of risk index was assessed using area under the
receiver-operating curve (AUC). The Hosmer–Lemeshow good-
ness-of-fit statistic was used to test the calibration.
RESULTS
Derivation of clinical scale. Demographic and clinical character-
istics are summarised in Table 1. The majority of the derivation
cohort patients (n¼ 228) were agedo65 years (126 patients, 55.3%)
and male (148 patients, 64.9%), with M1c metastatic stage (n¼ 133,
58.3%) and ECOG performance status 0 (157 patients, 68.9%).
Sixty-eight patients had liver metastasis (29.8%), 132 patients
had lung metastasis (57.9%) and only 50 patients had brain
metastasis (21.9%). Less than 50% of patients were treated
previously with targeted therapy (54 patients, 23.7%). However,
the majority of patients were treated previously with ipilimumab
(147 patients, 64.5%). Of the 228 derivation cohort patients, 44.3%
responded to anti-PD-1 therapy (101 of 228) while 55.7% did not
respond (127 of 228).
Table 2 presents all variables associated with response to
anti-PD-1 monotherapy on univariate analysis. Age o65 years
(OR¼ 0.42 (0.24, 0.72), Po0.001), elevated LDH (OR¼ 0.38 (0.21,
0.69), Po0.001), female sex (OR¼ 0.50 (0.29, 0.89), P¼ 0.01),
previous ipilimumab treatment (OR¼ 0.35 (0.20, 0.62), Po0.001)
and liver metastasis (OR¼ 0.34 (0.17, 0.62), Po0.001) were
significantly associated with lower response to anti-PD-1 therapy.
The following variables were tested and found not to be associated
with response to anti-PD-1 on univariate analysis: BRAF status
(OR¼ 0.76 (0.42–1.37, P¼ 0.37), brain metastasis (OR¼ 0.88
(0.47–1.67), P¼ 0.71), lung metastasis (OR¼ 1.6 (0.94–2.80),
P¼ 0.08), WBC count (OR¼ 0.99 (0.47–2.10), P¼ 0.72) and
metastatic status (M1b; OR¼ 1.93 (0.83–4.5) P¼ 0.12, M1c;
OR¼ 0.85 (0.42–1.73), P¼ 0.66, 3c; OR¼ 1.33 (0.17–01.4),
P¼ 0.78).
Table 3 presents the Cox regression analysis and the clinical
scoring model for response to anti-PD-1 therapy. In the forward
stepwise logistic regression model, female sex (OR¼ 0.51 (0.27,
0.94), P¼ 0.03), age o65 years (OR¼ 0.55 (0.30, 0.98), P¼ 0.04),
previous ipilimumab treatment (OR¼ 0.38 (0.20, 0.69), Po0.001),
elevated LDH (OR¼ 0.48 (0.25, 0.90), P¼ 0.02) and liver
metastasis (OR¼ 0.34 (0.17, 0.66), Po0.001) were found to be
significant.
A formula (clinical prediction scale) based on the estimated
coefficients from the logistic model was derived so that a score
ranging from 0 to 7 was calculated for each subject. An increase in
the score on the scale corresponded to a significantly lower
response to anti-PD-1 therapy (Po0.05). The final clinical
prediction scale included 5 prognostic factors that were signifi-
cantly correlated with lower response: female sex (1 point), age
o65 years (1 point), previous ipilimumab treatment (2 points),
elevated LDH (1 point), and the presence of liver metastasis (2
points). The developed scale had a fair performance in predicting
response to anti-PD-1: AUC 0.73 (95% CI 0.67, 0.80) (Figure 2A).
Validation of clinical prediction scale. Our scoring model was
validated in a separate cohort of patients. The validation cohort
included 87 patients diagnosed with advanced melanoma at
TACRI. Of the 87 validation cohort patients, 63.3% responded to
anti-PD-1 therapy (55 of 87), whereas 36.7% did not respond
(32 of 87). The scale maintained a discrimination power, AUC 0.70
(95% CI 0.58, 0.81) (Figure 2B). Table 4 presents the validation of
the clinical prediction scale by response probability. An increase in
the score on the scale corresponded to a lower probability of
337 patients with advanced melanoma treated with either pembrolizumab (2 or 10 mg kg–1
2Q3 or Q3W) or nivolumab (3 mg kg–1 Q2W) between December 2011 to October 2013
Excluded: 22 patients
with uveal melanoma
A total of 315 patients included
in the final cohort
Derivation cohort, N = 228 Validation cohort, N = 87
Cancer centres:
Cancer centres:
•
•
•
•
The Angeles clinic: KEYNOTE-001
UCSF: KEYNOTE-001/002/006
UCLA: KEYNOTE-001
University hospital of Zürich: KEYNOTE-
0029/006, EAP
Figure 1. Study participant selection criteria.
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response; the estimate probability of response for patients who
scored ‘6’ was 29% (95% CI 13, 52) and the estimate probability of
response for patients who scored ‘0’ was 87% (95% CI 71, 95).
None of the patients in the validation cohort scored ‘7’.
DISCUSSION
We developed and validated a clinical prediction scale for response
to anti-PD-1 monotherapy. The response index had good
predictive performance that was maintained in the validation
cohort with good calibration. The prediction scale to response to
anti-PD-1 was developed using stepwise logistic regression and
included five variables that were significantly associated with lower
response to anti-PD-1: female sex, age o65 years, history of
ipilimumab treatment, elevated LDH, and the presence of liver
metastasis.
Although anti-PD-1 therapy has transformed the systemic
treatment of advanced melanoma, the majority of patients still fail
to respond to anti-PD-1 monotherapy; the clinical data indicates
that the response rates for patients treated with anti-PD-1
immunotherapy rarely exceed 45% (Brahmer et al, 2010; Hamid
et al, 2013; Ribas et al, 2016). In this study, the response rate of the
derivation cohort was about 44.3%, which is consistent with the
literature.
As understanding and exploiting this clinical heterogeneity
could result in better outcomes, biomarker research remains a very
active area of clinical investigation, and characteristics of the
tumour microenvironment have been shown to predict response to
immunotherapy (Tumeh et al, 2014; Blank et al, 2016; Daud et al,
2016; Pitt et al, 2016). Assays for PD-L1 upregulation and
characterisation of a partially exhausted T-cell phenotype, for
example, have been strongly associated with effective response to
anti-PD-1 (Herbst et al, 2014; Taube et al, 2014; Tumeh et al, 2014;
Daud et al, 2016).
To date, however, there is less understanding of the impact of
host factors on response to PD-1 blockade. A recent study
investigating baseline biomarkers predicting outcomes of pembro-
lizumab-treated melanoma patients reported a better prognosis for
patients with high relative eosinophil count, high relative
lymphocyte count, low LDH and the absence of metastasis other
than soft tissue/lung (Weide et al, 2016). Additional characteristics,
such as age, diet, germline polymorphisms, pre-existing
Table 2. Variables significantly associated with response to
anti-PD-1 on univariate analysis
Source
Objective
response
rate
(ORR),a %
Odds ratio
(OR) (95% CI) P value
Total cohort 44.3 NA NA
Age o65 years 34.9 0.42 (0.24, 0.72) o0.001
Elevated LDHb 29.5 0.38 (0.21, 0.69) o0.001
Female sex 33.8 0.50 (0.29, 0.89) 0.01
Previous ipilimumab treatment 35.4 0.35 (0.20, 0.62) o0.001
Liver metastasis 26.5 0.34 (0.17, 0.62) o0.001
Abbreviations: CI¼ confidence interval; LDH¼ lactate dehydrogenase; NA¼ not applic-
able.
aORR was defined as the percentage of patients with a complete or partial response.
bDefined as LDH ratio 41.
Table 1. Patient characteristics of the derivation and
validation cohorts
No. (%)a
Variable Derivation (n¼228) Validation (n¼87)
Age, years
Mean±s.d. 62.5±13.1 62.1±14.3
Age o65 years 126 (55.3) 51 (58.6)
Sex
Male 148 (64.9) 62 (71.3)
Female 80 (35.1) 25 (28.7)
Primary site
Cutaneous 200 (87.7) 68 (78.2)
Mucosal 13 (5.7) 11 (12.6)
Unknown 15 (6.6) 8 (9.2)
M category (AJCC 2009)
Unresectable stage 3 4 (1.8) 3 (3.4)
M1a 42 (18.4) 8 (9.2)
M1b 49 (21.5) 11 (12.6)
M1c 133 (58.3) 65 (74.7)
ECOG performance status
0 157 (68.9) 75(86.2)
1 65 (28.5) 12 (13.8)
2 5 (2.2) 0 (0.0)
3 1 (0.4) 0 (0.0)
LDH
Normalb 150 (65.8) 49 (56.3)
Elevatedc 78 (34.2) 38 (43.7)
WBC
Mean±s.d. 7.1±3.5 6.6±1.9
BRAF mutation status
Negative 162 (72.0) 56 (65.1)
Positive 63 (28.0) 30 (34.9)
Unknown 3 (1.3) 1 (1.1)
Liver metastasis
No 160 (70.2) 66 (75.9)
Yes 68 (29.8) 21 (24.1)
Lung metastasis
No 96 (42.1) 46 (52.9)
Yes 132 (57.9) 41 (47.1)
Brain metastasis
No 178 (78.1) 71 (81.6)
Yes 50 (21.9) 16 (18.4)
Previous ipilimumab treatment
No 81 (35.5) 46 (52.9)
Yes 147 (64.5) 41 (47.1)
Previous targeted therapy
No 174 (76.3) 68 (78.2)
Yes 54 (23.7) 19 (21.8)
Abbreviations: AJCC¼American Joint Committee on Cancer; ECOG¼Eastern Coopera-
tive Oncology Group; LDH¼ lactate dehydrogenase; WBC¼white blood cell.
aValues are reported as no. (%) unless otherwise indicated.
bDefined as LDH ratio p1.
cDefined as LDH ratio 41.
Table 3. Cox regression analysis and clinical scoring model for
response to anti-PD-1 therapy
Variable
Odds ratio (OR)
(95% CI) P value Scoring
Female 0.51 (0.27, 0.94) 0.03 1
Age o65 years 0.55 (0.30, 0.98) 0.04 1
Previous ipilimumab treatment 0.38 (0.20, 0.69) o0.001 2
Elevated LDHa 0.48 (0.25, 0.90) 0.02 1
Liver metastasis 0.34 (0.17, 0.66) o0.001 2
Abbreviations: CI¼ confidence interval; LDH¼ lactate dehydrogenase.
aDefined as LDH ratio 41.
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immunosuppression and chronic infections, and the gut micro-
biome have been also proposed to influence response to immune
checkpoint inhibition (Pitt et al, 2016; Spranger et al, 2016).
The effect of age, in particular, has been an area of debate. An
aging, senescent immune system has been long thought to
experience many alterations, including an increase in suppressive
immune cell populations, such as MDSCs and Treg cells (Pawelec
et al, 2010; Goronzy and Weyand, 2013), and MDSCs have been
reported as potential predictors of resistance to ipilimumab
therapy (Meyer et al, 2014; Martens et al, 2016), which would
suggest a similar effect in anti-PD-1-treated patients.
Interestingly, a recent meta-analysis (Nishijima et al, 2016)
comparing efficacy of immune checkpoint inhibition in younger
and older patients showed overall survival benefit in both groups,
although an exception was seen in a subgroup of older patients in
four anti-PD-1 trials who did not demonstrate OS improvement.
Although this is different than our findings that younger age is
correlated with decreased anti-PD-1 efficacy, it is interesting to
note that the age cutoff used for this analysis was X75 years.
Although there was no OS benefit observed in patients aged X75
years, a consistent survival benefit was still observed in patients
aged 65–75 years. Although this observation was made at the meta-
analysis level and across a heterogeneous group of clinical trials
and needs to be confirmed with adequate power, this preliminary
data seems to suggest that patients over a certain age do just as well
as their younger counterparts and, in light of our scoring model
correlating greater anti-PD-1 efficacy in patients aged X65 years,
potentially may have even better response. This observation is
certainly hypothesis generating and needs further prospective
validation.
The role of sex in response to immunotherapy is also much
debated. Although female sex was found to be a negative
prognostic indicator in our model, the mechanisms of this remain
poorly defined. Indeed, much of the current literature actually
supports a survival benefit for females with advanced melanoma,
although of note, much of this data preceded the advent of
immune checkpoint inhibition (Manola et al, 2000; Dronca et al,
2013; Nosrati and Wei, 2014). Though it is speculated that the
increased number and/or improved function of tumour-specific
T-helper cells in women could underlie this clinical observation,
data regarding the role of sex-hormone modulation of PD-1 are
currently limited to preclinical models (Polanczyk et al, 2006,
2007). Further work of this nature needs to be carried out to
identify and elucidate the nature of sex-dependent differences in
immunoregulatory pathways in patients with advanced cancer
(Dronca and Dong, 2015).
Given the relative novelty of this field, the influence of host
factors on immunotherapy response requires further research. The
factors elucidated in this clinical scale represent one further step in
that direction, while also addressing the pressing clinical need for a
clinical prediction-scoring model to help guide treatment choice. A
model to identify those patients who are likely to respond to anti-
PD-1 monotherapy would spare them the additional toxicity of
combination CTLA-4/PD-1 blockade; conversely, the ability to
identify patients who are unlikely to respond to PD-1 monotherapy
would also be helpful in determining the most appropriate
treatment option. Those patients, for example, may have improved
outcomes with molecularly targeted agents (if their melanomas
harbour BRAF V600 mutations) or with a more aggressive
immunotherapy regimen (combination ipilimumab/nivolumab)
or a clinical trial, rather than with an anti-PD-1 agent alone.
Although our study included a large cohort of patients from
four different centres, considering the retrospective nature of this
study, a patient selection bias cannot be excluded. Additionally,
even though our scoring model had a fair prediction probability for
response in the validation cohort, this is based on a relatively small
sample of patients, and prospective validation with a larger sample
is needed. Additionally, the high response rate in our validation
cohort (63.3%) could have affected the ROC reported in our study.
Furthermore, the effect of active brain metastasis on patients’
response was not studied as the trials included in our study
excluded patients with active brain metastasis. Finally, we could
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Figure 2. Receiver operation characteristic curve to predict response
to immunotherapy. (A) Derivation cohort, area under the curve (AUC) 0.73
(95% CI 0.67–0.80). (B) Validation cohort, AUC 0.70 (95% CI 0.58–0.81).
Table 4. Validation of clinical prediction scale, response
probability (n¼87)
Response, n (%)
Response
score No Yes Total
Estimated response
probability (%)
(95% CI)
0 1 (12.5) 7 (87.5) 8 (100) 87 (71, 95)
1 4 (23.5) 13 (76.4) 17 (100) 81 (66, 90)
2 3 (17.6) 14 (82.3) 17 (100) 72 (60, 82)
3 4 (40.0) 6 (60.0) 10 (100) 62 (51, 72)
4 14 (60.8) 9 (39.1) 23 (100) 51 (37, 64)
5 2 (28.5) 5 (71.4) 7 (100) 39 (24, 58)
6 4 (80.0) 1 (20.0) 5 (100) 29 (13, 52)
7a NA NA NA NA
Total 32 (36.7) 55 (63.2) 87 (100) NA
Abbreviations: CI¼ confidence interval; NA¼ not applicable.
aNone of the patients in the validation cohort scored 7.
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not study the effect of pretreatment with ipilimumab in a separate
independent model owing to a low number of ipilimumab-naive
patients. However, in the four centres included in our study,
treatment with pembrolizumab was initiated in a minimum of 6
weeks following the last ipilimumab treatment.
To our knowledge, this is the first clinical scoring model
developed to predict response to anti-PD-1 monotherapy. This
scoring model was developed in a large cohort of patients who
were treated with anti-PD-1 monotherapy and validated in a
unique set of patients from a separate facility in an effort to
strengthen its external validity. Although biomarker development
in immunotherapeutics remains an active area of research, most
biomarkers to date require accession of tumour tissue and complex
laboratory diagnostics to predict response. With this scale, we
sought to create a clinical tool that would be readily accessible in a
wide range of clinical settings, without the need for additional
biopsies or complex computing.
We acknowledge that our scale is only the beginning and
additional data regarding host factors, and tumour characteristics
from ongoing studies will greatly help in refining and modifying
the current effort.
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